原发性脑肿瘤患者放疗后卒中特异性死亡风险
该研究基于SEER数据库纳入1992至2015年组织学确诊的原发性脑肿瘤患者85,284例,评估放疗对5年卒中特异性死亡的影响。总体5年累积卒中特异性死亡率为0.6%,未治疗组最高(0.76%)且多发生在诊断后1个月内,单纯放疗组(0.27%)和放疗加手术组(0.24%)较低且发生较晚。放疗未增加卒中特异性死亡风险,但放疗后风险在诊断后3.5至4年达峰。
要点
- 总体5年累积卒中特异性死亡率为0.6%,未治疗组最高(0.76%)且多在诊断后1个月内。
- 单纯放疗组(0.27%)和放疗加手术组(0.24%)卒中特异性死亡率较低且发生较晚。
- 放疗未增加卒中特异性死亡风险,但放疗后风险在诊断后3.5至4年达峰。
核心结论
- 原发性脑肿瘤患者卒中特异性死亡风险低,且放疗未增加该风险。
- 观察到两种模式:未治疗组发生急性卒中死亡,放疗(加或不加手术)组发生迟发性卒中死亡,后者在诊断后3.5至4年达峰。
研究设计与样本
- 研究为基于监测、流行病学和最终结果(SEER)数据库的分析,纳入1992至2015年组织学确诊的原发性脑肿瘤患者,任何年龄。
- 共分析85,284例患者,主要结局为放疗对5年卒中特异性死亡的影响。
- 采用竞争风险假设计算累积卒中特异性死亡率,并按干预类型分层;估计时间依赖风险比以确定放疗影响最大的时间。
主要发现
- 总体5年累积卒中特异性死亡率为0.6%。
- 未治疗组5年累积卒中特异性死亡率为0.76%,为最高,且卒中死亡主要发生在诊断后1个月内。
- 单纯放疗组5年累积卒中特异性死亡率为0.27%,放疗加手术组为0.24%,且这些组卒中相关死亡发生较晚。
- 上述模式在胶质母细胞瘤和非胶质母细胞瘤患者中均观察到;接受放疗的非胶质母细胞瘤患者卒中死亡倾向于发生更晚。
- 相对于未治疗组,放疗患者卒中死亡风险最高出现在诊断后3.5至4年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Stroke is an established complication in cancer patients, amongst whom brain tumour patients have the highest risk of fatal stroke. Radiotherapy is an important treatment for brain tumours and is associated with increased risk of cerebrovascular disease. However, the impact of brain irradiation on stroke-related deaths in brain tumour patients is unknown, and the timing of any effect uncertain. This study investigates the relationship between radiotherapy and stroke-specific mortality (SSM) in patients with primary brain tumours. METHODS: Patients of any age diagnosed with histologically confirmed primary brain tumours between 1992 and 2015 were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database. Primary outcome was impact of radiotherapy on 5-year SSM. Cumulative SSM rates under competing risk assumptions were estimated and stratified by intervention type. Time-dependent hazard ratios were estimated to identify when the radiotherapy impact was greatest. RESULTS: 85,284 patients with primary brain tumour diagnoses were analysed. Overall, the 5-year cumulative SSM rate was low (0.6%) with the highest rate (0.76%) in patients receiving no treatment, in whom it mainly occurred < 1 month after diagnosis. SSM rates were lower in patients treated with radiotherapy alone (0.27%) or radiotherapy plus surgery (0.24%); stroke-related deaths also occurred later in these groups. While these patterns were observed in both glioblastoma and non-glioblastoma patients, stroke deaths tended to occur later in non-glioblastoma patients receiving radiotherapy. Relative to the 'no treatment' group, the highest risk of stroke mortality in radiotherapy treated patients occurred 3.5-4 years after diagnosis. CONCLUSION: The risk of SSM is low in patients with primary brain tumours and is not increased by radiotherapy. Two different patterns were observed: acute stroke mortality in patients receiving no treatment, and delayed stroke mortality in patients receiving radiotherapy (+/- surgery) with the latter peaking 3.5-4 years after diagnosis.
引用
- Kouli O, McLoone P, Morrison D, et al. Risk of stroke-specific mortality after radiotherapy in patients with primary brain tumours. Clin Transl Radiat Oncol. 2023. PMID: 37502698. doi:10.1016/j.ctro.2023.100658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。